Esophageal Cancer

New England Journal of Medicine

Volumn 349, Issue 23, 2003, Pages 2241-2252

  Enzinger, Peter C ^a   Mayer, Robert J ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CIGARETTE SMOKE CONDENSATE; CISPLATIN; DOCETAXEL; FLUOROURACIL; PACLITAXEL;

ADENOCARCINOMA; ADVANCED CANCER; AIRWAY OBSTRUCTION; ALCOHOL CONSUMPTION; BARRETT ESOPHAGUS; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER INCIDENCE; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CIGARETTE SMOKING; CONSERVATIVE TREATMENT; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DYSPHAGIA; ESOPHAGUS ACHALASIA; ESOPHAGUS CARCINOMA; GASTROESOPHAGEAL REFLUX; GENETIC SUSCEPTIBILITY; HEAD AND NECK CARCINOMA; HUMAN; MORBID OBESITY; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; PATHOPHYSIOLOGY; POVERTY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TRACHEOESOPHAGEAL FISTULA; TREATMENT PLANNING; TYLOSIS;

ADENOCARCINOMA; ALCOHOL DRINKING; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DEGLUTITION DISORDERS; ESOPHAGEAL FISTULA; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HUMANS; INCIDENCE; NEOPLASM STAGING; PREOPERATIVE CARE; RISK FACTORS; SMOKING;

EID: 0344874654     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra035010     Document Type: Review

References (122)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Pies LAG, Eisner MP, Kosary C, et al., eds. SEER cancer statistics review, 1973-1999. Bethesda, Md.: National Cancer Institute, 2002. (Accessed November 6, 2003, at http://seer.cancer.gov/csr/1973_1999/esoph.pdf.)
3. Daly JM, Fry WA, Little AG, et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 2000;190:562-72.
4. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29. [Erratum, Int J Cancer 1999;83:870-3.]
5. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29. [Erratum, Int J Cancer 1999;83:870-3.]
6. Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001;234:360-7.
7. Terry P, Lagergren J, Ye W, Nyren O, Wolk A. Antioxidants and cancers of the esophagus and gastric cardia. Int J Cancer 2000;87:750-4.
8. Collard J-M, Otte J-B, Fiasse R, et al. Skeletonizing en bloc esophagectomy for cancer. Ann Surg 2001;234:25-32.
9. Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinoma of the stomach and esophagus (United States). Cancer Causes Control 2001;12:721-32.
10. Brown LM, Hoover R, Silverman D, et al. Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidemiol 2001;153:114-22.
11. De Stefani E, Barrios E, Fierro L. Black (air-cured) and blond (flue-cured) tobacco and cancer risk. III. Oesophageal cancer. Eur J Cancer 1993;29A:763-6.
12. Ahsan H, Neugut A. Radiation therapy for breast cancer and increased risk for esophageal carcinoma. Ann Intern Med 1998;128:114-7.
13. Erkal HS, Mendenhall WM, Amdur RJ, Villaret DB, Stringer SP. Synchronous and metachronous squamous cell carcinomas of the head and neck mucosal sites. J Clin Oncol 2001;19:1358-62.
14. Sandler RS, Nyren O, Ekbom A, Eisen GM, Yuen J, Josefsson S. The risk of esophageal cancer in patients with achalasia: a population-based study. JAMA 1995;274:1359-62.
15. Avisar E, Luketich J. Adenocarcinoma in a mid-esophageal diverticulum. Ann Thorac Surg 2000;69:288-9.
16. Garidou A, Tzonou A, Lipworth L, Signorello LB, Kalapothaki V, Trichopoulos D. Life-style factors and medical conditions in relation to esophageal cancer by histologic type in a low-risk population. Int J Cancer 1996;68:295-9.
17. Ghavamzadeh A, Moussavi A, Jahani M, Rastegarpanah M, Iravani M. Esophageal cancer in Iran. Semin Oncol 2001;28:153-7.
18. Csikos M, Horvath O, Petri A, Petri I, Imre J. Late malignant transformation of chronic corrosive oesophageal strictures. Langenbecks Arch Chir 1985;365:231-8.
19. Risk JM, Mills HS, Garde J, et al. The tylosis esophageal cancer (TOC) locus: more thanjust a familial cancer gene. Dis Esophagus 1999;12:173-6.
20. Ellis A, Field JK, Field EA, et al. Tylosis associated with carcinoma of the oesophagus and oral leukoplakia in a large Liverpool family - a review of six generations. Eur J Cancer B Oral Oncol 1994;30B:102-12.
21. Larsson LG, Sandstrom A, Westling P. Relationship of Plummer-Vinson disease to cancer of the upper alimentary tract in Sweden. Cancer Res 1975;35:3308-16.
22. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
23. Farrow DC, Vaughan TL, Sweeney C, et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 2000;11:231-8.
24. Vaughan TL, Farrow DC, Hansten PD, et al. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev 1998;7:749-56.
25. Lagergren J, Bergstrom R, Adami HO, Nyren O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000;133:165-75.
26. Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998;115:50-7.
27. Warburton-Timms VJ, Charlett A, Valori RM, et al. The significance of cagA(+) Helicobacter pylori in reflux oesophagitis. Gut 2001;49:341-6.
28. Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998;58:588-90.
29. Wu AH, Crabtree JE, Bernstein L, et al. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer 2003;103:815-21.
30. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150-5.
31. Lagergren J, Bergstrom R, Nyren O. No relation between body-mass and gastrooesophageal reflux symptoms in a Swedish population based study. Gut 2000;47:26-9.
32. Nilsson M, Lundegardh G, Carling L, Ye W, Lagergren J. Body mass and reflux oesophagitis: an oestrogen-dependent association? Scand J Gastroenterol 2002;37:626-30.
33. Romeo Y, Cameron AJ, Schaid DJ, et al. Barrett's esophagus: prevalence in symptomatic relatives. Am J Gastroenterol 2002;97:1127-32.
34. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002;123:461-7.
35. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 2002;287:1972-81.
36. Walch AK, Zitzelsberger HF, Bruch J, et al. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol 2000;156:555-66.
37. Varis A, Puolakkainen P, Savolainen H, et al. DNA copy number profiling in esophageal Barrett adenocarcinoma: comparison with gastric adenocarcinoma and esophageal squamous cell carcinoma. Cancer Genet Cytogenet 2001;127:53-8.
38. Wijnhoven BP, Tilanus HW, Dinjens WN. Molecular biology of Barrett's adenocarcinoma. Ann Surg 2001;233:322-37.
39. Singh SP, Lipman J, Goldman H, et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998;58:1730-5.
40. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000;118:487-96.
41. Katada N, Hinder RA, Smyrk TC, et al. Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus. Arch Surg 1997;132:728-33.
42. Arber N, Lightdale C, Rotterdam H, et al. Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 1996;5:457-9.
43. Yacoub L, Goldman H, Odze RD. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. Mod Pathol 1997;10:105-12.
44. Polkowski W, van Sandick JW, Offerhaus GJ, et al. Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 1999;6:290-7.
45. Krishnadath KK, Tilanus HW, van Blankenstein M, et al. Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol 1997;182:331-8.
46. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
47. Daly JM, Karnell LH, Menck HR. National Cancer Data Base report on esophageal carcinoma. Cancer 1996;78:1820-8.
48. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without postoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-33.
49. Burmeister BH, Smithers BM, Fitzgerald L, et al. A randomized phase III trial of preoperative chemoradiation followed by surgery (CR-S) versus surgery alone (S) for localized resectable cancer of the esophagus. Prog Proc Am Soc Clin Oncol 2002;21:130a. abstract.
50. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26:Suppl 15:2-8.
51. Gammon MD, Schoenberg JB, Ahsan H, et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997;89:1277-84.
52. Terry P, Lagergren J, Hansen H, Wolk A, Nyren O. Fruit and vegetable consumption in the prevention of oesophageal and cardia cancers. Eur J Cancer Prev 2001;10:365-9.
53. Jochem VJ, Fuerst PA, Fromkes JJ. Familial Barrett's esophagus associated with adenocarcinoma. Gastroenterology 1992;102:1400-2.
54. Lagergren J, Ye W, Lindgren A, Nyren O. Heredity and risk ofcancer of the esophagus and gastric cardia. Cancer Epidemiol Biomarkers Prev 2000;9:757-60.
55. Yang H, Berner A, Mei Q, et al. Cytologic screening for esophageal cancer in a high-risk population in Anyang County, China. Acta Cytol 2002;46:445-52.
56. Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998;93:536-41.
57. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999;94:2037-42.
58. Spechler SJ. Barrett's esophagus. N Engl J Med 2002;346:836-42.
59. Sharma P, Sampliner R, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997;92:582-5.
60. Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999;45:489-94. [Erratum, Gut 2000;47:154-5.]
61. Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999;45:489-94. [Erratum, Gut 2000;47:154-5.]
62. Morales TG, Sampliner RE. Barrett's esophagus: update on screening, surveillance, and treatment. Arch Intern Med 1999;159:1411-6.
63. Sharma P. Current status of ablative therapies in esophageal disorders. Curr Gastroenterol Rep 2001;3:219-24.
64. Falk GW, Rice TW, Goldblum JR, Richter JE. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 1999;49:170-6.
65. Morris CD, Byrne JP, Armstrong GR, Attwood SE. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation. Br J Surg 2001;88:1357-62.
66. Corti L, Skarlatos J, Boso C, et al. Outcome of patients receiving photodynamic therapy for early esophageal cancer. Int J Radiat Oncol Biol Phys 2000;47:419-24.
67. Sharma P, Jaffe PE, Bhattacharyya A, Sampliner RE. Laser and multipolar electrocoagulation ablation of early Barrett's adenocarcinoma: long-term follow-up. Gastrointest Endosc 1999;49:442-6.
68. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9.
69. Fein R., Kelsen DP, Geller N, Bains M, McCormack P, Brennan MF. Adenocarcinoma of the esophagus and gastroesophageal juncfion: prognostic factors and results of therapy. Cancer 1985;56:2512-8.
70. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976;21:953-6.
71. Van Dam J. Endosonographic evaluation of the patient with esophageal cancer. Chest 1997;112:Suppl:184S-190S.
72. Vazquez-Sequeiros E, Norton ID, Clain JE, et al. Impact of EUS-guided fine-needle aspiration on lymph node staging in patients with esophageal carcinoma. Gastrointest Endosc 2001;53:751-7.
73. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18:3202-10.
74. Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003;21:428-32.
75. Krasna MI, Flowers JL, Attar S, McLaughlin J. Combined thoracoscopic/laparoscopic staging of esophageal cancer. J Thorac Cardiovasc Surg 1996;111:800-6.
76. Mealy K, Feely J, Reid I, McSweeney J, Walsh T, Hennessy TP. Tumor marker detection in oesophageal carcinoma. Eur J Surg Oncol 1996;22:505-7.
77. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag, 2002.
78. Pera M, Trastek VF, Carpenter HA, Allen MS, Deschamps C, Pairolero PC. Barrett's esophagus with high-grade dysplasia: an indication for esophagectomy? Ann Thorac Surg 1992;54:1999-204.
79. Headrick JR, Nichols FC III, Miller DL, et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg 2002;73:1697-702.
80. Reed CE. Surgical management of esophageal carcinoma. Oncologist 1999;4:95-105.
81. Hulscher JBF, van Sandick JW, de Boer AGEM, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662-9.
82. Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. Semin Oncol 1999;26:Suppl 15:12-20.
83. Marriette C, Maurel A, Fabre S, Balon J-M, Triboulet J-P. Facteurs prognostiques préopératoires des cancers épidermoïdes de l'oesophage thoracique. Gastroenterol Clin Biol 2001;25:468-72.
84. Hosch SB, Stoecklein NH, Pichlmeier U, et al. Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol 2001;19:1970-5.
85. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-13.
86. Swanson SJ, Batirel HF, Bueno R, et al. Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg 2001;72:1918-25.
87. Enzinger PC, Kulke MH, Clark JW, et al. Phase II trial of CPT-11 in previously untreated patients with advanced adenocarcinoma of the esophagus and stomach. Prog Proc Am Soc Clin Oncol 2000;19:315a. abstract.
88. De Besi P, Sileni VC, Salvagno L, et al. Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer. Cancer Treat Rep 1986;70:909-10.
89. Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000;6:316-23.
90. Ilson DH, Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999;17:3270-5.
91. Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216-20.
92. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-7.
93. Ross P, Nicolson D, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004.
94. Pommier RF, Vetto JT, Ferris BL, Wilmarth TJ. Relationships between operative approaches and outcomes in esophageal cancer. Am J Surg 1998;175:422-5.
95. Goldminc M, Maddern G, Le Prise E, Meunier B, Campion JP, Launois B. Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg 1993;80:367-70.
96. Bosset J-F, Gignoux M, Triboulet J-P, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-7.
97. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-84.
98. Earlam R, Cunha-Melo JK. Oesophageal squamous cell carcinoma. II. A critical review of radiotherapy. Br J Surg 1980;67:457-61.
99. Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). Int J Radiat Oncol Biol Phys 1998;41:579-83.
100. Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy: the second Scandinavian trial in esophageal carcinoma. World J Surg 1992;16:1104-10.
101. Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994;73:1179-84.
102. Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994;41:391-3.
103. Walsh T, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-7. [Erratum, N Engl J Med 1999;341:384.]
104. Walsh T, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-7. [Erratum, N Engl J Med 1999;341:384.]
105. Law S, Kwong D, Tung H, et al. Preoperative chemoradiation for squamous cell esophageal cancer: a prospective randomized trial. Can J Gastroenterol 1998;12:Suppl B:56B. abstract.
106. Teniere P, Hay JM, Fingerhut A, Fagniez PL. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. Surg Gynecol Obstet 1991;173:123-30.
107. Fok M, Sham JS, Choy D, Cheng SW, Wong J. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 1993;113:138-47.
108. Ando N, Iizuka T, Kakegawa T, et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997;114:205-9.
109. Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-8.
110. al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277-84. [Erratum, J Clin Oncol 1997;15:866.]
111. al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277-84. [Erratum, J Clin Oncol 1997;15:866.]
112. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999;281:1623-7.
113. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167-74.
114. Bedenne L, Michel P, Bouche O, et al. Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Prog Proc Am Soc Clin Oncol 2002;21:130a. abstract.
115. Kelsen DP, Minsky B, Smith M, et al. Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy. J Clin Oncol 1990;8:1352-61.
116. Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastroesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994;5:609-16.
117. Spiridonidis CH, Laufman LR, Jones JJ, Gray DJ, Cho CC, Young DC. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma. Cancer 1996;78:2070-7.
118. Adam A, Ellul J, Watkinson AF, et al. Palliation of inoperable esophageal carcinoma: a prospective randomized trial of laser therapy and stent placement. Radiology 1997;202:344-8.
119. Dallal HJ, Smith GD, Grieve DC, Ghosh S, Penman ID, Palmer KR. A randomized trial of thermal ablative therapy versus expandable metal stents in the palliative treatment of patients with esophageal carcinoma. Gastrointest Endosc 2001;54:549-57.
120. Canto MI, Smith C, McClelland L, et al. Randomized trial of PDT vs. stent for palliation of malignant dysphagia: cost-effectiveness and quality of life. Gastrointest Endosc 2002;55:Suppl:AB100. abstract.
121. Burt M, Diehl W, Martini N, et al. Malignant esophagorespiratory fistula: management options and survival. Ann Thorac Surg 1991;52:1222-8.
122. Raijman I, Siddique I, Ajani J, Lynch P. Palliation of malignant dysphagia and fistulae with coated expandable metal stents: experience with 101 patients. Gastrointest Endosc 1998;48:172-9.